Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
science & technology (138) 138
life sciences & biomedicine (136) 136
oncology (125) 125
female (113) 113
male (105) 105
middle aged (104) 104
aged (96) 96
adult (86) 86
biological and medical sciences (74) 74
medical sciences (74) 74
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
lung neoplasms - drug therapy (50) 50
treatment outcome (42) 42
antineoplastic agents (40) 40
chemotherapy (39) 39
pharmacology. drug treatments (38) 38
cisplatin - administration & dosage (37) 37
tumors (36) 36
aged, 80 and over (32) 32
cancer (31) 31
lung neoplasms - pathology (31) 31
abridged index medicus (30) 30
neoplasm staging (30) 30
survival rate (29) 29
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
carcinoma, squamous cell - drug therapy (28) 28
prognosis (28) 28
head and neck neoplasms - drug therapy (27) 27
combined modality therapy (25) 25
disease-free survival (25) 25
radiotherapy (25) 25
antineoplastic agents - therapeutic use (24) 24
survival analysis (24) 24
carcinoma, non-small-cell lung - drug therapy (22) 22
animals (20) 20
carcinoma, squamous cell - pathology (20) 20
care and treatment (20) 20
head and neck cancer (20) 20
head and neck neoplasms - pathology (20) 20
research (20) 20
retrospective studies (19) 19
follow-up studies (18) 18
squamous cell carcinoma (18) 18
dose-response relationship, drug (16) 16
etoposide - administration & dosage (16) 16
lung cancer (16) 16
lung neoplasms - genetics (16) 16
lung neoplasms - mortality (16) 16
carcinoma, small cell - drug therapy (15) 15
cisplatin (15) 15
otorhinolaryngology. stomatology (15) 15
drug administration schedule (14) 14
paclitaxel - administration & dosage (14) 14
pneumology (14) 14
radiology, nuclear medicine & medical imaging (14) 14
tumors of the respiratory system and mediastinum (14) 14
drug therapy (13) 13
otorhinolaryngology (13) 13
small cell lung carcinoma - pathology (13) 13
carcinoma, squamous cell - mortality (12) 12
cell line, tumor (12) 12
disease progression (12) 12
maximum tolerated dose (12) 12
mice (12) 12
mutation (12) 12
neoplasm recurrence, local - drug therapy (12) 12
neutropenia - chemically induced (12) 12
small cell lung carcinoma - drug therapy (12) 12
carcinoma, non-small-cell lung - pathology (11) 11
chemotherapy, adjuvant (11) 11
general aspects (11) 11
health aspects (11) 11
hematology, oncology and palliative medicine (11) 11
nasopharyngeal carcinoma (11) 11
remission induction (11) 11
surgery (11) 11
carcinoma, squamous cell - therapy (10) 10
fluorouracil - administration & dosage (10) 10
head and neck neoplasms - mortality (10) 10
lymphatic metastasis (10) 10
mice, nude (10) 10
neoplasm metastasis (10) 10
neoplasm recurrence, local (10) 10
patients (10) 10
survival (10) 10
adolescent (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
carcinoma, squamous cell - radiotherapy (9) 9
cisplatin - adverse effects (9) 9
evaluation (9) 9
immunohistochemistry (9) 9
lung neoplasms - therapy (9) 9
radiotherapy, adjuvant (9) 9
upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology (9) 9
xenograft model antitumor assays (9) 9
carcinoma, squamous cell - secondary (8) 8
clinical trials (8) 8
combined treatments (8) 8
epidermal growth factor receptor (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
by Rudin, Charles M, Prof and Pietanza, M Catherine, MD and Bauer, Todd M, MD and Ready, Neal, Prof and Morgensztern, Daniel, MD and Glisson, Bonnie S, Prof and Byers, Lauren A, MD and Johnson, Melissa L, MD and Burris, Howard A, MD and Robert, Francisco, Prof and Han, Tae H, PhD and Bheddah, Sheila, BA and Theiss, Noah, MS and Watson, Sky, BS and Mathur, Deepan, MD and Vennapusa, Bharathi, MD and Zayed, Hany, PhD and Lally, Satwant, MS and Strickland, Donald K, MD and Govindan, Ramaswamy, Prof and Dylla, Scott J, PhD and Peng, Stanford L, MD and Spigel, David R, MD and SCRX16-001 investigators and SCRX16-001 Investigators
The lancet oncology, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 42 - 51
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Large Cell - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Intracellular Signaling Peptides and Proteins - immunology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Small Cell Lung Carcinoma - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - immunology | Neoplasm Recurrence, Local - pathology | Immunoconjugates - pharmacology | Carcinoma, Large Cell - immunology | Immunoconjugates - therapeutic use | Female | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Neuroendocrine - drug therapy | Membrane Proteins - immunology | Survival Rate | Lung Neoplasms - immunology | Maximum Tolerated Dose | Small Cell Lung Carcinoma - pathology | Carcinoma, Neuroendocrine - immunology | Carcinoma, Neuroendocrine - pathology | Aged | Neoplasm Staging | Benzodiazepinones - therapeutic use | Small Cell Lung Carcinoma - immunology | Viral antibodies | Antibodies | Relapse | Lung cancer | Biopharmaceutics | Diseases | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
by Curran, Michael A and Glisson, Bonnie S
Annual review of medicine, ISSN 0066-4219, 1/2019, Volume 70, Issue 1, pp. 409 - 424
4-1BB | CTLA-4 | vaccines | PD-1 | immunotherapy | Immunotherapy - methods | Risk Assessment | Cancer Vaccines - administration & dosage | Humans | Immunologic Factors - administration & dosage | Male | Treatment Outcome | CTLA-4 Antigen - immunology | Forecasting | Prostatic Neoplasms - immunology | Prostatic Neoplasms - therapy | Cancer Vaccines - immunology | CTLA-4 Antigen - administration & dosage | Cell Transformation, Neoplastic - immunology | Neoplasms - therapy | Animals | Neoplasms - immunology | Pancreatic Neoplasms - immunology | Female | T-Lymphocytes - immunology | Neoplasms - pathology | Pancreatic Neoplasms - therapy | Cancer vaccines | T cells | Health aspects | Immunotherapy | Enzyme inhibitors | Innovations | Cell proliferation | Antigens | Transformation | Cell survival | Immune response | Vaccination | Lymphocytes T | Vaccines | Immunological tolerance | Cell activation | Immune checkpoint | Lymphocytes | Modulation | Attenuation | Mutation | Proteomes | Cancer | Tumors | Immune system | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
by Arlene A. Forastiere and Qiang Zhang and Randal S. Weber and Moshe H. Maor and Helmuth Goepfert and Thomas F. Pajak and William Morrison and Bonnie Glisson and Andy Trotti and John A. Ridge and Wade Thorstad and Henry Wagner and John F. Ensley and Jay S. Cooper
Journal of clinical oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 845 - 852
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology | Tumors | Follow-Up Studies | Deglutition - drug effects | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Male | Chemoradiotherapy | Laryngectomy | Cisplatin - administration & dosage | Laryngeal Neoplasms - pathology | Larynx - radiation effects | Organ Sparing Treatments - methods | Laryngeal Neoplasms - therapy | Fluorouracil - administration & dosage | Adult | Female | Laryngeal Neoplasms - physiopathology | Radiotherapy, Adjuvant | Deglutition - radiation effects | Speech - drug effects | Kaplan-Meier Estimate | Carcinoma, Squamous Cell - therapy | Treatment Outcome | Carcinoma, Squamous Cell - physiopathology | Larynx - drug effects | Remission Induction | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Speech - radiation effects | Aged | Neoplasm Staging | Salvage Therapy - methods | Index Medicus | Original Reports | Hnc13 | Hnc6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
by Lee, Nancy Y, Dr and Zhang, Qiang, PhD and Pfister, David G, Prof and Kim, John, MD and Garden, Adam S, Prof and Mechalakos, James, PhD and Hu, Kenneth, MD and Le, Quynh T, MD and Colevas, A Dimitrios, MD and Glisson, Bonnie S, MD and Chan, Anthony TC, Prof and Ang, K Kian, Prof
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 172 - 180
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Chemoradiotherapy - methods | Nasopharyngeal Carcinoma | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma | Humans | Middle Aged | Nasopharyngeal Neoplasms - therapy | Male | Bevacizumab | Nasopharyngeal Neoplasms - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Adult | Female | Neoplasm Staging | Antimitotic agents | Care and treatment | Product development | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
by Kris, Mark G and Johnson, Bruce E and Berry, Lynne D and Kwiatkowski, David J and Iafrate, A. John and Wistuba, Ignacio I and Varella-Garcia, Marileila and Franklin, Wilbur A and Aronson, Samuel L and Su, Pei-Fang and Shyr, Yu and Camidge, D. Ross and Sequist, Lecia V and Glisson, Bonnie S and Khuri, Fadlo R and Garon, Edward B and Pao, William and Rudin, Charles and Schiller, Joan and Haura, Eric B and Socinski, Mark and Shirai, Keisuke and Chen, Heidi and Giaccone, Giuseppe and Ladanyi, Marc and Kugler, Kelly and Minna, John D and Bunn, Paul A
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 19, pp. 1998 - 2006
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Pneumology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Adenocarcinoma of Lung | Humans | Middle Aged | Genotype | Male | Molecular Targeted Therapy | Multiplex Polymerase Chain Reaction | Adenocarcinoma - drug therapy | Proto-Oncogenes | Survival Analysis | Female | Adenocarcinoma - genetics | Aged | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Sequence Analysis, DNA - methods | Evaluation | Usage | Care and treatment | Physicians | Lung cancer | Therapeutics | Practice | Genetic screening | Homeopathy | Materia medica and therapeutics | Oncology | Biological assays | Genomics | Clinical outcomes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225
by Nancy Lee and Jonathan Harris and Adam S. Garden and William Straube and Bonnie Glisson and Ping Xia and Walter Bosch and William H. Morrison and Jeanne Quivey and Wade Thorstad and Christopher Jones and K. Kian Ang
Journal of clinical oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 22, pp. 3684 - 3690
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Otorhinolaryngology. Stomatology | Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology | Tumors | Confidence Intervals | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nasopharyngeal Neoplasms - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Radiotherapy, Intensity-Modulated - adverse effects | Cisplatin - administration & dosage | Nasopharyngeal Neoplasms - pathology | Dose-Response Relationship, Drug | Young Adult | Nasopharyngeal Neoplasms - radiotherapy | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Time Factors | Adult | Female | Nasopharyngeal Neoplasms - drug therapy | Drug Administration Schedule | Risk Assessment | Radiotherapy, Intensity-Modulated - methods | Kaplan-Meier Estimate | Probability | Treatment Outcome | Combined Modality Therapy | Disease-Free Survival | Radiation Injuries - epidemiology | Maximum Tolerated Dose | Adolescent | Survival Analysis | Cisplatin - adverse effects | Radiation Injuries - pathology | Aged | Neoplasm Staging | Dose-Response Relationship, Radiation | Index Medicus | Original Reports | Hnc12 | Hnc11 | Radn
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib
by Sen, Triparna and Tong, Pan and Stewart, C. Allison and Cristea, Sandra and Valliani, Aly and Shames, David S and Redwood, Abena B and Fan, You Hong and Li, Lerong and Glisson, Bonnie S and Minna, John D and Sage, Julien and Gibbons, Don L and Piwnica-Worms, Helen and Heymach, John V and Wang, Jing and Byers, Lauren Averett
Cancer research (Chicago, Ill.), ISSN 0008-5472, 07/2017, Volume 77, Issue 14, pp. 3870 - 3884
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Lung Neoplasms - drug therapy | Humans | Pyrazines - administration & dosage | Small Cell Lung Carcinoma - enzymology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Gene Knockdown Techniques | Biomarkers, Tumor - metabolism | Female | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Phthalazines - administration & dosage | Checkpoint Kinase 1 - antagonists & inhibitors | Small Cell Lung Carcinoma - genetics | Cisplatin - pharmacology | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Checkpoint Kinase 1 - metabolism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Pyrazoles - administration & dosage | Small Cell Lung Carcinoma - pathology | Animals | Mice, Nude | Cell Line, Tumor | Mice | Pyrazines - pharmacology | Checkpoint Kinase 1 - genetics | Medical research | Cell culture | Effectiveness | Small cell lung carcinoma | RNA-mediated interference | CHK1 protein | Lung cancer | Clinical trials | Poly(ADP-ribose) polymerase | Pharmacology | Myc protein | Kinases | Cisplatin | Anticancer properties | Amplification | Inhibitors | Platinum | Biomarkers | Antitumor activity | Inhibition | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The impact of smoking and tp53 mutations in lung adenocarcinoma patients with targetable mutations—the lung cancer mutation consortium (LCMC2)
by Aisner, Dara L and Sholl, Lynette M and Berry, Lynne D and Rossi, Michael R and Chen, Heidi and Fujimoto, Junya and Moreira, Andre L and Ramalingam, Suresh S and Villaruz, Liza C and Otterson, Gregory A and Haura, Eric and Politi, Katerina and Glisson, Bonnie and Cetnar, Jeremy and Garon, Edward B and Schiller, Joan and Waqar, Saiama N and Sequist, Lecia V and Brahmer, Julie and Shyr, Yu and Kugler, Kelly and Wistuba, Ignacio I and Johnson, Bruce E and Minna, John D and Kris, Mark G and Bunn, Paul A and Kwiatkowski, David J and LCMC2 Investigators and LCMC2 investigators
Clinical cancer research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1038 - 1047
Life Sciences & Biomedicine | Oncology | Science & Technology | Smoking - adverse effects | Lung Neoplasms - drug therapy | Prognosis | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Tumor Suppressor Protein p53 - genetics | Young Adult | Adenocarcinoma of Lung - mortality | DNA Mutational Analysis | Adenocarcinoma of Lung - drug therapy | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Adenocarcinoma of Lung - etiology | Carcinogenesis - genetics | Treatment Outcome | Smoking - epidemiology | Survival Analysis | Aged | Biomarkers, Tumor - genetics | High-Throughput Nucleotide Sequencing | Mutation | Adenocarcinoma | Therapy | Epidermal growth factor receptors | p53 Protein | Lung cancer | Patients | Survival | ErbB-2 protein | Gene sequencing | Consortia | Alterations | Genotyping | Experimental design | Tumor suppressor genes | Smoking | Cancer | Index Medicus | mutation | TP53 | targetable | EGFR | lung adenocarcinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Novel strategies for the treatment of small-cell lung carcinoma
by William, William N and Glisson, Bonnie S
Nature reviews. Clinical oncology, ISSN 1759-4774, 10/2011, Volume 8, Issue 10, pp. 611 - 619
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Antineoplastic Agents - therapeutic use | Small Cell Lung Carcinoma - drug therapy | Humans | Care and treatment | Chemotherapy | Prognosis | Lung cancer, Small cell | Research | Radiotherapy | Health aspects | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial
by Gold, Kathryn A and Kies, Merrill S and William, William N and Johnson, Faye M and Lee, J. Jack and Glisson, Bonnie S
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2169 - 2173
skin cancer | anti‐neoplastic agents | erlotinib | epidermal growth factor receptor | squamous cell carcinoma | anti-neoplastic agents | Life Sciences & Biomedicine | Oncology | Science & Technology | Clinical trials | Squamous cell carcinoma | Dosage and administration | Research | Erlotinib | Drug therapy | Tyrosine | Therapy | Epidermal growth factor receptors | Toxicity | Malignancy | Metastasis | Disease control | Patients | Survival | Metastases | Confidence intervals | Epidermal growth factor | Response rates | Growth factors | Protein-tyrosine kinase | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights